Heart Transplantation Clinical Trial
Official title:
Urinary Proteomics in Predicting Heart Transplantation Outcomes
uPROPHET aims to validate urinary proteomics for risk stratification and monitoring graft performance is recipients of heart transplants
The proof of concept underlying uPROPHET rests on the EPLORE findings that capillary electrophoresis coupled with high-resolution mass-spectroscopy reproducibly identified unique urinary proteomic (UP) signatures associated with subclinical left ventricular dysfunction, renal impairment and adverse cardiovascular outcomes. Consensus criteria currently applied for the selection of patients for heart transplantation (HTx) leave an inconvenient margin of uncertainty, because of the unpredictable course of the disease and the shortage of donor hearts. Furthermore, monitoring graft function and adjusting immunosuppression remain major challenges after HTx. Endomyocardial biopsies, up to 20 in the first year after HTx, are the standard approach to detect graft rejection, but require an invasive risk-carrying procedure. uPROPHET aims to develop UP profiling: (1) as a prognostic tool helpful in selecting terminally ill heart failure patients for HTx with the greatest probability of survival while adding a maximum of high-quality years to life; and (2) as an instrument to monitor graft performance and immune system activity and to manage immunosuppression. The new UP classifiers will be initially validated by demonstrating analogy between the proteomic profiles in urine and tissue samples of explanted hearts. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06035991 -
First Clinical Evaluation of Heart Transplantation With Grafts Preserved Using an Ex-vivo Extended Perfusion System
|
N/A | |
| Recruiting |
NCT01927614 -
Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy
|
N/A | |
| Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
| Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
| Completed |
NCT01028599 -
Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients
|
N/A | |
| Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
| Terminated |
NCT00420537 -
Shift to Everolimus (RAD) Kidney Sparing Study
|
Phase 4 | |
| Enrolling by invitation |
NCT03292861 -
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
|
Phase 2 | |
| Recruiting |
NCT04924491 -
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05270902 -
Haemoadsorption During Heart Transplantation
|
N/A | |
| Completed |
NCT05289180 -
Brachial Right Ventricle - Endomyocardial Biopsy
|
||
| Recruiting |
NCT03687723 -
Observational Study of the Clinical Use of the OCS™ Heart
|
||
| Completed |
NCT01091194 -
Effect of Exercise After Heart Transplantation
|
Phase 2 | |
| Completed |
NCT01182571 -
Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients
|
N/A | |
| Terminated |
NCT00678002 -
Quality of Life in Pediatric Transplant Patients
|
||
| Withdrawn |
NCT00780637 -
Brachial Artery t-PA Release in Heart Transplant Recipients
|
N/A | |
| Withdrawn |
NCT00780377 -
Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients
|
N/A | |
| Withdrawn |
NCT00572286 -
Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study
|
N/A | |
| Terminated |
NCT00121784 -
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
|
Phase 4 | |
| Completed |
NCT00123331 -
Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation
|
Phase 4 |